ACKR3 and breast carcinoma: Similar results were observed when metastatic breast cancer MDA-MB-231 cells, which express high levels of endogenous ACKR3 and CXCR468, were treated with the ACKR3-targeting nanobodies (Supplementary Fig. 12).